Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$108.99 USD
-1.77 (-1.60%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $108.98 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Balance Sheet
Fiscal Year End for Jazz Pharmaceuticals PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,626 | 881 | 591 | 2,133 | 1,077 |
Receivables | 706 | 651 | 563 | 396 | 356 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 597 | 714 | 1,073 | 95 | 79 |
Other Current Assets | 506 | 359 | 384 | 215 | 118 |
Total Current Assets | 3,435 | 2,606 | 2,611 | 2,840 | 1,630 |
Net Property & Equipment | 170 | 228 | 257 | 128 | 132 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 484 | 386 | 323 | 260 | 229 |
Intangibles | 7,171 | 7,487 | 8,980 | 3,153 | 3,361 |
Deposits & Other Assets | 67 | 55 | 41 | 26 | 48 |
Total Assets | 11,393 | 10,835 | 12,299 | 6,536 | 5,539 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 103 | 91 | 100 | 27 | 48 |
Current Portion Long-Term Debt | 605 | 31 | 31 | 246 | 33 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 794 | 803 | 666 | 353 | 268 |
Income Taxes Payable | 35 | 8 | 10 | 25 | 11 |
Other Current Liabilities | 0 | 0 | 2 | 3 | 5 |
Total Current Liabilities | 1,537 | 933 | 809 | 654 | 364 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 848 | 944 | 1,301 | 133 | 229 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 5,108 | 5,693 | 6,019 | 1,849 | 1,574 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 105 | 107 | 117 | 101 | 109 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 7,656 | 7,750 | 8,333 | 2,876 | 2,428 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 3,700 | 3,477 | 3,535 | 2,634 | 2,266 |
Retained Earnings | 879 | 734 | 831 | 1,160 | 1,068 |
Other Equity | -842 | -1,126 | -400 | -134 | -223 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3,737 | 3,086 | 3,965 | 3,660 | 3,111 |
Total Liabilities & Shareholder's Equity | 11,393 | 10,835 | 12,299 | 6,536 | 5,539 |
Total Common Equity | 3,737 | 3,086 | 3,965 | 3,660 | 3,111 |
Shares Outstanding | 62.90 | 62.90 | 61.40 | 55.70 | 56.50 |
Book Value Per Share | 59.41 | 49.06 | 64.58 | 65.70 | 55.06 |
Fiscal Year End for Jazz Pharmaceuticals PLC falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,981 | 1,818 | 1,626 | 1,586 | 1,362 |
Receivables | 698 | 707 | 706 | 628 | 610 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 543 | 577 | 597 | 612 | 657 |
Other Current Assets | 460 | 437 | 506 | 420 | 380 |
Total Current Assets | 3,682 | 3,540 | 3,435 | 3,246 | 3,010 |
Net Property & Equipment | 169 | 166 | 170 | 222 | 229 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 551 | 514 | 484 | 472 | 438 |
Intangibles | 6,815 | 6,975 | 7,171 | 7,123 | 7,448 |
Deposits & Other Assets | 71 | 71 | 67 | 76 | 66 |
Total Assets | 11,362 | 11,327 | 11,393 | 11,204 | 11,261 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 97 | 81 | 103 | 110 | 98 |
Current Portion Long-Term Debt | 606 | 605 | 605 | 605 | 31 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 801 | 827 | 794 | 770 | 748 |
Income Taxes Payable | 52 | 49 | 35 | 89 | 68 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 1,556 | 1,562 | 1,537 | 1,573 | 945 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 775 | 810 | 848 | 841 | 911 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 5,101 | 5,105 | 5,108 | 5,111 | 5,687 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 99 | 105 | 127 | 127 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 7,599 | 7,631 | 7,656 | 7,715 | 7,735 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 3,779 | 3,714 | 3,700 | 3,640 | 3,580 |
Retained Earnings | 872 | 865 | 879 | 885 | 812 |
Other Equity | -888 | -882 | -842 | -1,035 | -867 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3,763 | 3,696 | 3,737 | 3,489 | 3,526 |
Total Liabilities & Shareholder's Equity | 11,362 | 11,327 | 11,393 | 11,204 | 11,261 |
Total Common Equity | 3,763 | 3,696 | 3,737 | 3,489 | 3,526 |
Shares Outstanding | 61.70 | 63.00 | 62.90 | 63.10 | 64.10 |
Book Value Per Share | 60.98 | 58.67 | 59.41 | 55.30 | 55.00 |